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Abstract
Background: Little isknownonwhether centralised andspecialisedcombined pharmacological andpsychologicalintervention
inthe early phase of severe unipolardepression improveprognosis. The aim of the presentstudy was toassessthe benefits and
harms of centralised and specialised secondary care intervention in the early course of severe unipolar depression.
Methods: A randomised multicentre trial with central randomisation and blinding in relation to the primary outcome
comparing a centralised and specialised outpatient intervention program with standard decentralised psychiatric treatment.
The interventions were offered at discharge from first, second, or third hospitalisation due to a single depressive episode or
recurrent depressive disorder. The primary outcome was time to readmission to psychiatric hospital. The data on re-
hospitalisation was obtained from the Danish Psychiatric Central Register. The secondary and tertiary outcomes were
severity of depressive symptoms according to the Major Depression Inventory, adherence to medical treatment, and
satisfaction with treatment according to the total score on the Verona Service Satisfaction Scale-Affective Disorder (VSSS-A).
These outcomes were assessed using questionnaires one year after discharge from hospital.
Results: A total of 268 patients with unipolar depression were included. There was no significant difference in the time to
readmission (unadjusted hazard ratio 0.89, 95% confidence interval 0.60 to 1.32; log rank: x
2=0.3, d.f.=1, p=0.6); severity of
depressive symptoms (mood disorder clinic: median 21.6, quartiles 9.7–31.2 versus standard treatment: median 20.2, quartiles
10.0–29.8; p=0.7); or the prevalence of patients in antidepressant treatment (73.9% versus 80.0%, p=0.2). Centralised and
specialised secondary care intervention resulted in significantly higher satisfaction with treatment (131 (SD 31.8) versus 107 (SD
25.6); p,0.001).
Conclusions: Centralised and specialised secondary care intervention in the early course of severe unipolar depression resulted
in no significant effects on time to rehospitalisation, severity of symptoms, or use of antidepressants, but increased patient
satisfaction.
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Introduction
Unipolar depressive disorder is associated with a high risk of
relapse of depression and the risk of relapse increases as the number
ofpreviousepisodesincreases[1,2].Manypatients donotrecoverto
previous psychosocial function [3], some patients present with
cognitive impairment also during remitted phase [4], and the risk of
developing dementia seems to be increased in the long run [5,6].
The tendency to relapse can be reduced by continued treatment
with antidepressants [7], and potentially by cognitive behavioural
therapy [8]. Nevertheless, results from naturalistic follow-up
studies suggest that the progressive development of the diseases
is not prevented in clinical practice with the present treatments [9–
11]. Part of the explanation my be decreased adherence with
antidepressants [12–15] and delayed intervention with pharma-
cological and psychological treatment programs. A number of
studies have investigated the effect of combined or sequential
pharmacological and psychological interventions [8] and various
health-service interventions in recurrent depressive disorder [16–
21] but none of studies have specifically investigated the effect in
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32950the early stage of severe depressive disorder. There are indirect
suggestions that early intervention may improve the course and
outcome. Antidepressants prescribed for depressive disorder may
have neuroprotective abilities [22,23] and patients may profit from
psychotherapy before potential cognitive disturbances may occur
during the long-term course of illness [24].
The aim of the present trial was to investigate the benefits and
harms of centralised and specialised outpatient combined
pharmacological and psychological intervention compared with
standard psychiatric outpatient treatment early in the course of
severe depressive disorder (unipolar disorder). The trial design was
pragmatic with very few exclusion criteria and investigated the
effect among patients following psychiatric hospitalisation in The
Capital Region of Denmark. This pragmatic design was chosen to
obtain a high generalisability of results from the trial to clinical
settings regarding patients with the most severe depressive
disorders [25].
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Trial design
The trial protocol has been described in details elsewhere [26].
A summary of the design and methods is presented in the
following.
Participants
A total of 268 patients with unipolar depression episode or
recurrent depressive disorder were included from seven (Psychi-
atric Centre Hvidovre, Psychiatric Centre Copenhagen, Rigshos-
pitalet; Psychiatric Centre Amager, Psychiatric Centre Frederiks-
berg, Psychiatric Centre Copenhagen, Bispebjerg, Psychiatric
Centre Gentofte, Psychiatric Centre Hillerød) out of the nine
psychiatric wards in The Capital Region of Denmark during a
period from December 2005 to December 2009.
Inclusion and exclusion criteria
Inclusion. Patients discharged from their first, second, or
third hospitalisation from an inpatient psychiatric ward with an
ICD-10 diagnosis of single moderate or severe depressive episode
or recurrent depressive disorder (ICD-10 code: DF32.1–33.9) as
the primary diagnosis. Comorbidity with alcohol or substance
abuse and other psychiatric disorders were allowed. The
physicians at the psychiatric wards diagnosed the patients. Age
was between 18 and 70 year old. The patients were able and
willing to give written and oral informed content.
Exclusion. Patients with moderate or severe dementia; with
poor understanding of Danish; under any kind of commitment; or
without informed consent were excluded.
Randomisation
Patients were randomised to the intervention group or the
control group at the end of the index hospitalisation while still in
hospital. The Copenhagen Trial Unit conducted randomisation
centrally according to a computer generated allocation sequence
to secure allocation concealment. Allocation was stratified for
psychiatric centre and number of hospitalisations for depression (1
or 2 compared to 3). The ratio of randomisation between the
intervention and the control group was 1:1. The randomisation
was carried out with a block size of 20 unknown to the
investigators.
Blinding
Blinding of patients and the treating clinicians was not possible
as patients were randomised to the mood disorder clinic or to
standard treatment. The primary outcome was based on public
register data using blinding for intervention. All other outcomes
were assessed without blinding to the intervention. Two
researchers (HVH and LVK) carried out all statistical analyses
before the primary outcome data were unblinded.
Experimental intervention group
Patients in the intervention group were treated in a specialised
outpatient mood disorder clinic at the Psychiatric Centre
Copenhagen, Copenhagen University Hospital, Rigshospitalet.
The clinic was established September 2004 in parallel to the work
and publication of a Health Technology Assessment (HTA) report
on outpatient treatment in severe affective disorders [27].
The staff in the outpatient mood disorder clinic consists of full
time specialists in psychiatry with specific clinical experience and
knowledge on diagnosis and treatment of affective disorders as well
as certified psychologists, nurses, and a social worker with
experience in affective disorders.
During the first year following establishment of the clinic a
detailed intervention program including manuals for psychological
group interventions (psychoeducation and cognitive behavioural
therapy) was developed, tested, and revised in a pilot phase with
inclusion of approximately 30 patients. The manuals in Danish are
available by contact to the last author (LVK). The final combined
pharmacological and non-pharmacological intervention program
was as follows. The intervention program lasted one year.
According to the protocol, a medical doctor evaluated all patients
in the clinic less than two weeks after discharge from the
psychiatric inpatient ward. Although most patients improve during
hospitalisation for depressive disorder, it is well known that they do
still suffer from depressive symptoms at discharge from wards in
the Copenhagen area [28]. Prior course of illness and effect of
treatment was carefully recorded and diagnosis and treatment
plans were re-evaluated and current pharmacological treatment
adjusted in accordance with clinical status and national [29] and
international guidelines [30,31].
Subsequently, the physician at the mood clinic followed the
patients with regular appointments depending on their clinical
status and needs. In addition, patients participated in three
different sequential group sessions weekly. All treatments sessions
were carried out in accordance with manuals although individu-
alised according to characteristics and needs of the patients in the
group. The first group was a settling-in group for patients just
discharged from hospitalisation. Here the focus was on the current
clinical status and beliefs and experiences in relation to the recent
hospitalisation. Patients stayed in this group until they were
clinically stable and had at least partly remitted from depressive
symptoms (HDS-17 items ,14), i.e., typically for some months up
to half a year. When stable, the patients were transferred to the
second and intermediary group, consisting of either group
psychoeducation or cognitive behavioural therapy. The type of
group therapy was decided in concordance between the patient
and the clinicians. These group sessions consist of 1K hours
intervention every week for 12 consecutive weeks. In both groups,
focus was on knowledge and acceptance of suffering from a
unipolar depressive disorder, identifying depressive symptoms
from normal reactions, personal identity in relation to suffering
from a depressive disorder, risk situations, stress management, the
need for sustained pharmacological maintenance treatment,
adverse effects to treatment, and identification of individual prior
early warning signs of upcoming depressive episodes. In addition,
Specialised Outpatient Treatment for Depression
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cognitive distortions in identity and behaviour and to some extend
on inter-individual conflicts. Finally, the patients joined a 3–6
months discharge group that was a preparation for re-referral
either to the general practitioner, a private psychiatrist, or to the
community mental health centre with the aim of identifying
individual early warning signals prospectively in practice and
training of how to change upcoming personal conflicts and
cognitive distortions.
Six to eight patients and two therapists (psychiatrist and
psychologist or nurse) participated in each group. In the cognitive
behavioural groups, at least one therapist had a formal education
in cognitive behavioural therapy.
Control group
The control group of patients were offered standard care
consisting of the standard mental health service routines in The
Capital Region of Denmark, i.e., treatment at the general
practitioner, a private psychiatrist, or at the local community
mental health centre. Participation in the trial had no influence on
the treatment offered to these patients. Psychopharmacological
treatment in the control group, compared with treatment in the
mood disorder clinic, is likely more based on the preferences of the
individual physician than on national and international guidelines.
Psychosocial treatment elements like psychoeducation and cogni-
tive behavioural therapy, and contact with family might be
provided infrequently and in a less intensive, non-systematic way
and presumably only for some patients as compared with the
mood disorder clinic.
Main outcome measures
The primary outcome was time to first readmission to
psychiatric ward after discharge from the index hospitalisation
(in the Trial registration report (www.ClinicalTrials.gov: ID:
NCT00253071), the time frame to first readmission was specified
to 2, 5, and 10 years, respectively, however, in the statistical
analyses (see later) we included all follow-up time for all individuals
in one primary analysis drawing more information from the
available data).
Data on re-hospitalisation were obtained from the Danish
Psychiatric Central Register that contains data on all inpatient and
outpatient contacts to all psychiatric hospital-based services in
Denmark [32]. Since 1 January 1994, the ICD-10 has been in use
by the Register [33].
The secondary and the tertiary outcomes were assessed using
questionnaires that were mailed to all participants one year after
discharge from the index hospitalisation. The patients fulfilled the
Major Depression Inventory (MDI) [34–36] and The Mood
Disorder Questionnaire (MDQ) [37,38] to measure severity of
depressive symptoms and the prevalence of a hypomanic (or
manic) episode. A hypomanic or manic episode was defined as a
score of seven or more on the MDQ. When answering the MDI
one year after discharge the patients were asked about depressive
symptoms during the two weeks period with the worst symptoms
within the last year. In addition, the patients were asked whether
they were treated with maintenance medical treatment, antide-
pressant treatment, mood stabilizers, or antipsychotics.
The tertiary outcome was satisfaction with the intervention one
year after discharge from the index hospitalisation estimated by
the Verona Service Satisfaction Scale [39] adjusted to patients
with affective disorder, Verona Service Satisfaction Scale-Affective
Disorder (VSSS-A) [40] (inclusion of VSSS-A as a tertiary
outcome was not specified in the trial registration report but in
the trial protocol [26], which was published before inclusion of
data and statistical analyses). VSSS-A includes among others 32
different items on satisfaction with care within seven different areas
(overall satisfaction, professionals’ skills and behaviour, informa-
tion, access, efficacy, types of intervention, relative’s involvement).
Patients rate each item on a five-point Likert scale (1=terrible,
2=mostly dissatisfactory, 3=mixed, 4=mostly satisfactory,
5=excellent) making it possible to calculate a mean total score
of satisfaction (between 0–5).
Sample size estimation
The sample size estimation has been described in detail
elsewhere [26]. Based on results from the Health Technology
Assessment (HTA) report on outpatient treatment in severe
affective disorders [27], it was estimated that systematic outpatient
combination treatment consisting of prophylactic pharmacother-
apy and psychotherapy/psychoeducation compared to either
medication alone or psychotherapy/psychoeducation alone could
reduce the rate of recurrence of affective episodes between 14%
and 44% and the rate of readmission with 35% during the first
year after discharge from hospital. Anticipating a hazard ratio
(HR) of 0.65 in the comparison of the intervention group with the
control group on the primary outcome; a two-sided risk of type 1
error, a, of 0.05; a type 2 error risk, b, of 20%; (power of 80%) and
equal group size, the sample size (N) for was calculated to N=176
under the further assumption of a median time to re-hospitalisa-
tion of approximately 6 months in the control group, an inclusion
period of 36 months, and a follow up period of 12 months. As the
present trial ran in parallel to a trial aiming to include 176 patients
with bipolar disorder, we decided to expand the inclusion period
of the present trial with one year to a total of four years, as we had
to expand the trial duration of the bipolar trial due to decreased
recruitment.
The actual inclusion of 268 patients with unipolar depression
over a four-year period results in a power of 93% for the detection
or rejection of a HR of 0.65; of 82% to detect or reject a HR of
0.70; and of 63% to detect or reject a HR of 0.75.
Statistical analysis
The statistical analyses were conducted as intention-to-treat
analyses. Regarding the primary outcome, time to the first re-
hospitalisation was estimated in a Kaplan-Meier plot, censoring at
the date of death or end of study, and the difference in cumulated
prevention of re-hospitalisation in the intervention and in the
control group was tested in a log-rank test.
Hazard ratios (HR) adjusted for age, sex, psychiatric centre and
number of previous psychiatric admissions were calculated in Cox’
regression models.
Participants and non-participants were compared using register-
based variables to evaluate whether participants in the trial were
representative of patients with depressive disorder, discharged
from their first, second, or third hospitalisation.
SPSS 19.0 for windows was used for the statistical analyses.
Ethical considerations
The trial was approved by the Danish Research Ethical
Committee (KF 01 272130), covering all hospitals in the region,
the Danish Data Protection Agency (CVR-nr. 11088037-29) and
the Danish National Board of Health. There was written informed
consent from all patient involved in the trial, including consent to
participate in the trial and consent to publish, where appropriate.
Furthermore, the trial was registered at http://www.clinicaltrials.
gov (ID: NCT00253071).
The participant’s unique and personal identification number
was submitted to the Danish National Board of Health to link with
Specialised Outpatient Treatment for Depression
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Medical Register on Vital Statistics.
Results
According to the Danish Psychiatric Central Register, 2327
patients fulfilled the inclusion criteria as they got an ICD-10
diagnosis of a single depressive episode or recurrent unipolar
depression (F 32.1–F33.9) at discharge from their first, second or
third psychiatric hospitalisation during the study period from
December 1, 2005 to December 1, 2009. Among these potential
eligible patients, 268 patients were randomised, 131 patients to
treatment in the mood disorder clinic and 137 patients to standard
treatment. The remaining 2059 patients were either not assessed
for participation in the study (approximately 80%) or excluded due
to dementia, poor Danish, any kind of commitment, or lack of
informed consent. The 268 patients who participated in the trial
did not differ from the 2059 potentially eligible patients regarding
sex (female: 62.8% compared to 62.7%; p=1) but were
considerably younger (median 38 years (quartiles 31–53) com-
pared to median 45 years (quartiles 31–60); p,0.001). Figure 1 is a
flow diagram of patients in the trial.
The intervention in principle started at the date of discharge
from the index hospitalisation as patients before discharge was
allocated to receive treatment in the mood disorder clinic versus
standard treatment. As national register based data on the
Figure 1. Consort flow diagram.
doi:10.1371/journal.pone.0032950.g001
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included patients and as risk time was calculated from the
discharge date to readmission date, death, or end of study follow-
up. No patient was lost to follow-up and no patient was excluded
from the analyses.
The two intervention groups seemed reasonably well balanced
regarding baseline variables, except for marital status where there
was an uneven distribution of widowed patients (Table 1).
Register-based data on re-hospitalisation and death was 100%
complete, i.e., available for all 268 included patients. The patients
were followed to the first event, a re-admission at psychiatric
hospital, or to the date of death or end of study on October 8
th,
2010, whatever came first. Five patients died during follow-up,
four patients treated in the mood disorder clinic (one due to suicide
shortly after entering the clinic and three after having stopped in
the clinic) and one in the standard treatment group.
In Figure 2, it can be seen from the Kaplan-Meier curves that
patients treated in the mood disorder clinic and patients who got
standard treatment did not differ significantly regarding the time to
first readmission. Table 2 presents time to readmission for the two
groups and a log rank test confirmed that there was no statistical
significant difference between the two groups (x
2=0.3, d.f.=1,
p=0.6; unadjusted HR 0.89, 95% CI 0.60 to 1.32; p=0.6). When
adjusted for the effect of age, sex, psychiatric centre, and number of
previous psychiatric admissions in a Cox’ regression model, there
was no statistically significant difference between the intervention
groups (HR 0.81, 95% CI 0.53 to 1.22; p=0.3).
A post-hoc explorative sub-group analysis was made in relation
to the primary outcome stratifying according to the number of
prior hospitalisations. Figure 3 shows Kaplan-Meier curves of time
to readmission for the sub-group of patients with two or more
prior hospitalisations, (n=80, 44 in the mood disorder clinic group
and 36 in the standard treatment group). There was no statistically
significant differences in time to psychiatric readmission (x
2=1.4,
d.f.=1, p=0.24; unadjusted HR 0.69, 95% CI 0.37 to 1.28;
p=0.2). Similarly, there were no significant differences in time to
psychiatric readmission between the intervention groups for the
188 patients with one prior hospitalisation (unadjusted HR 0.96,
95% CI 0.58 to 1.58; p=0.9), the 49 patients with two prior
hospitalisations (unadjusted HR 0.47, 95% CI 0.19 to 1.18;
p=0.1) or the 31 patients with three prior hospitalisations
(unadjusted HR 0.89, 95% CI 0.35 to 2.28; p=0.8).
One year after discharge from the index hospitalisation, 63%
of the 268 included patients fulfilled and returned the mailed
questionnaire without statistically significant difference between
the intervention and control groups (p=0.6). There was no
significant difference in the total score on the Major Depression
Inventory (MDI) (mood disorder clinic: median 21.6 (quartiles 9.7
to 31.2) versus standard treatment: median 20.2 (quartiles 10.0 to
29.8); p=0.7). Similarly, the prevalence of a hypomanic episode
according the Mood Disorder Questionnaire (MDQ) did not
differ at the one year follow-up (6.4% for patients in the mood
disorder clinic versus 6.1% for patients in standard treatment;
p=0.6).
There was a significant difference in the prevalence of use a
mood stabilizer (30.7% of patients treated in the mood disorder
clinic compared with 17.5% in the standard treatment group;
p=0.04) but no significant difference in the prevalence of use of
antidepressants (73.9% versus 80.0%, p=0.2) or antipsychotics
(12.2% versus 11.3%, p=0.5).
Satisfaction with treatment after one year showed a highly
significant difference between patients treated in the mood
disorder clinic versus patients who received standard treatment
(total score at VSSS-A: 131 (SD: 31.8) versus 107 (SD: 25.6);
p,0.001). The overall satisfaction (items 8, 17, 18) showed a
similar difference in mean score between the two groups 4.4 (SD:
1.0) versus 3.8 (SD: 1.0) in favour to the treatment in the mood
disorder clinic (p,0.001).
Table 1. Baseline socio-demographic characteristics, distribution of patients with or without previous admission before the index
hospitalisation, and distribution between centers.
The mood disorder clinic Standard treatment
Sex Men (%) 48 (36.4) 51 (37.2)
Female (%) 83 (63.4) 86 (62.8)
Median age at randomisation
(Quartiles)
38.4 (31.9–55.3) 38.7 (29.5–51.0)
Marital status Married (%) 28 (22.6) 25 (19.7)
Never been married (%) 69 (55.6) 70 (55.1)
Divorced/separated (%) 19 (15.3) 31 (24.4)
Widowed (%) 8 (6.5) 1 (0.8)
11 or more years of education (%) 71 (56.3) 79 (62.2)
Employment Employed (%) 52 (42.6) 61 (49.6)
Unemployed (%) 70 (57.4) 62 (50.4)
Number of patients with or without previous
admission before index hospitalisation
Without (%) 87 (66.4) 101 (73.7)
With (%) 44 (33.6) 36 (26.3)
Center Hvidovre (%) 60 (45.8) 65 (47.4)
Rigshospitalet (%) 40 (30.5) 36 (26.3)
Amager (%) 27 (20.6) 23 (16.8)
Others (%) 4 (3.1) 13 (9.5)
doi:10.1371/journal.pone.0032950.t001
Specialised Outpatient Treatment for Depression
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32950Discussion
The EIA trial showed no significant difference in time to
psychiatric re-admission, severity of depressive symptoms, or use of
pharmacological treatment (except for mood stabilizers) for
patients treated for one year in a specialised outpatient mood
disorder clinic versus patients offered standard outpatient
treatment. Nevertheless, patients allocated to the specialised clinic
were more satisfied with the care provided. There may be several
explanations for these findings.
In the effort to investigate patients with early and severe
depression the trial focused on patients discharged from their first,
second, or third psychiatric hospitalisation. A large proportion of
patients in the trial was discharged from their first psychiatric
hospitalisation ever(n=188outof268(70%),Table 1).The validity
of a clinical diagnosis of a single severe or moderate depressive
episode have been found to be moderately high, 82.8% and 76.0%
correct, respectively, according to a research based interview using
the Schedules for Clinical Assessment in Neuropsychiatry (SCAN,
[41]) in a prior Danish study on the validity of the diagnosis of a
single depressive episode [42]. Such patients with a single severe or
moderate depressive episode have a better prognosis with a lower
re-admission rate than patients with several admissions [43] and we
may infer from our trial that they do well with a les intensive
outpatient treatment and at least they did not differ statistically
significant in their re-admission rate from the mod clinic patients.
Figure 2. Time to readmission for patients treated in the mood disorder clinic versus standard care (all patients, N=268).
doi:10.1371/journal.pone.0032950.g002
Table 2. Comparison of time to readmission for patients treated in the mood disorder clinic versus standard treatment.
No. of
patients
No. of events
(readmissions,
(%))
No. of events
censored due
to death or
end of trial (%)
Mean, years of post-
randomisation follow up
(95% confidence interval) Log Rank Test
x
2 d.f. p
Treatment The mood disorder clinic 131 47 (34.3) 84 (64.1) 3.3 (2.9–3.6) 0.3 1 0.56
Standard treatment 137 55 (42.0) 82 (59.9) 3.1 (2.8–3.5)
doi:10.1371/journal.pone.0032950.t002
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in accordance with inclusion of a large proportion of patients with
a single depressive episode, who have a decreased rate of
readmission. Due to the low event rate, the trial was underpow-
ered, but we did not observe a statistically significant positive effect
of the mood disorder clinic, as illustrated in Figure 1 and as
reflected in the actual HR of 0.89, 95% CI 0.60 to 1.32. However,
the confidence interval opens up for both a 40% relative risk
reduction or a 32% relative risk increase and further trials are
needed to exclude both potential benefit and harm. Register data
on readmission were obtained one year after the end of the
inclusion period of the trial. As we found it scientifically stringent
to be blinded during the phases of data extraction and statistical
analyses regarding the primary outcome throughout the study
period we did not want to conduct interim analyses. Further
extension of the inclusion period to more than a four year period
would increase the risk of a rub-off effect from the ongoing
intervention in the mood disorder clinic to intervention in
standard clinical care (see later).
The patients in our trial with more severe disorders, i.e., those
who had prior psychiatric admissions, seemed to have a small
advantage of the interventions provided in the mood disorder
clinic – but this difference was statistically insignificant (Figure 3).
Findings from other studies suggest a better effect of combination
therapy, pharmacological and psychological in chronic and severe
depression than in less severely affected patients [44,45]. Anyway,
the present trial did not focus specifically on patients with more
than one prior psychiatric admission and consequently the sample
size of patients with more severe disorders was small (n=80)
resulting in decreased statistical power in this post-hoc subgroup
analysis.
Comorbidity with alcohol abuse was allowed and 16% of the
patients treated in the mood disorder clinic had alcohol abuse or
dependency. The same distribution is expected in the control
group due to the randomised design.
Bias cannot be excluded, as it was not possible to blind the
physicians in the mood disorder clinic or physicians at the wards in
relation to which group the patient was allocated to. Clinicians at
the psychiatric wards knew before the patients were discharged
from hospitalisation whether the patient was allocated to the mood
disorder clinic or to standard treatment. It is possible that patients
in the intervention group were discharged more early from the
index hospitalisation than patients in the standard treatment group
because they immediately after randomisation had a plan for
outpatient treatment. However, there was no statistical significant
difference in the duration of the index hospitalisation (mood
disorder clinic: median duration 36.5 days, quartiles 22.0 to 75.3
versus standard treatment: median duration 42.5 days, quartiles
23.0 to 80.8, p=0.6).
Time to (re)hospitalisation as an outcome has been criticised as
reductionistic. However, it benefits from being consistently
recorded and may have high face validity as admission to hospital
reflects serious relapse of the illness [46]. There was no formal
difference in the possibilities to re-admit patients or in practical
ways of doing so between the mood disorder clinic and the
psychiatric centres offering standard care. Nevertheless, it is
Figure 3. Time to readmission for patients treated in the mood disorder clinic versus standard care (only patients with two or more
prior hospitalisations, N=80).
doi:10.1371/journal.pone.0032950.g003
Specialised Outpatient Treatment for Depression
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32950possible that the decision to admit a patient in our trial were
influenced by the treating physician’s attitude toward centralised
and specialised treatment although it is not obvious which
directions such attitudes may cause. In the experimental group,
physicians in the mood disorder clinic may be reluctant to admit a
patient in order to increase the apparent benefits of the mood
disorder clinic or, alternatively, to admit the patient earlier or
more often as they were followed more closely. In the control
group, the physicians may have been eager to admit patients to
prove the advantages of the mood disorder clinic or, alternatively,
be reluctant to admit the patient to prove the benefit of standard
care.
It is possible that that treatment offered in standard care did not
differ much from treatment offered in the mood disorder clinic.
Thus, pharmacologically, only the use of mood stabilizers differed
between the patient groups (30.7% of patients treated in the mood
disorder clinic versus 17.5% in the standard treatment group;
p=0.04) whereas there were no significant differences in the use of
antidepressants (73.9% versus 80.0%, p=0.2) or antipsychotics
(12.2% versus 11.3%, p=0.5). Similarly, combined pharmacolog-
ical and psychological intervention was also offered to a great deal
of patients treated in standard care. In fact, 70.1% of patients in
standard care received individual therapy and 35.0% group
therapy in accordance with a growing uptake of these interven-
tions in standard treatment. Still, even though there was no
difference in the treatment response in the two groups, the patients
treated in the mood disorder clinic were more satisfied with the
treatment.
Limitations
It was not possible to blind patients or treating clinicians for the
intervention due to the nature of the intervention. The trial was
estimating the effect of a complex intervention in a centralised
mood disorder clinic versus standard treatment. The intervention
consisted of a combination of many different elements and it is not
be possible to differentiate the effect of the different intervention
components.
The patients in the experimental group received a well-defined
intervention program according to a manual. Less is known about
the treatment offered the patients in the control group. It is likely
that the patients in the control group received very different
interventions and that these interventions varied between broad,
competent and prolonged service to a much shorter and sporadic
treatment offer. Furthermore, the intervention in the control
group may have changed over the study period of four years to
become more similar to the intervention in the experimental group
because of increased focus on treatment of affective disorders
possible also due to the Danish HTA report [27], the growing
tendency to recommend combined pharmacological and psycho-
logical interventions for patients with unipolar disorder treated in
secondary health care [47,48], and because of a rub-off effect from
the many leading local clinicians involved in the allocation of
patients to the trial.
It should further be noted that according to answers on the
Mood Disorder Questionnaire [49,50] 6% to 8% of the patients
might have suffered from bipolar disorder type II, not recognised
by the clinicians at the local psychiatric ward. Finally, it should be
recognised that the response rate to the questionnaire was
disappointingly low (63%) increasing the possibility of selection
bias related to the answers between the intervention groups.
Generalisability
Pragmatic trials as the present trial are designed to measure
effectiveness; that is whether an intervention works when used in
usual conditions of care. To ensure applicability in the wide range
of usual care settings, pragmatic trials should include all kinds of
participants to whom the intervention may be offered in the real
world, if its effectiveness is established. The trial included a
moderately large number of patients suffering from depressive
disorder with all kinds of symptoms and comorbidities and with
very few exclusion criteria.
Perspective
Overall we did not find an effect of outpatient treatment in a
specialised mood disorder clinic versus standard treatment for
patients early in the course of severe unipolar disorder. It seems
reasonable to conclude from the trial that patients who have been
hospitalised for the first time because of a single depressive episode
may be treated decentralised after discharge by the general
practitioner, private psychiatrist, or community psychiatric health
centres. On the other hand, it cannot be excluded that patients
with more severe or chronic depression with two or more previous
psychiatric hospitalisations may benefit from a more specialised
treatment program but this trial did not have sufficient statistical
power to clarify this question. Future trials are needed to identify
the group of depressive patients, if any, who might benefit from a
more intensive and combined treatment program.
What is already known on this topic
It is not known whether centralised and specialised combined
pharmacological and psychological outpatient intervention in the
early phase of severe unipolar depressive disorder improve
prognosis compared with standard treatment.
What this study adds
Centralised and specialised secondary outpatient care interven-
tion following discharge from first, second or third psychiatric
hospitalisation with depression resulted in no significant effects on
time to rehospitalisation, severity of symptoms, or use of
antidepressants compared to standard decentralised treatment,
but in increased patient satisfaction.
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